Dr. Saud Sadiq announced that the Tisch MS Research Center of New York will be pursuing a Phase II clinical trial exploring the use of stem cells for treatment of multiple sclerosis (MS), planned to start in this fall. The announcement followed positive results from a FDA-approved Phase I stem cell trial for MS.
In the Phase I clinical trial, MS patients received multiple spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (called MSC-NPs).
Compellingly, the Phase I trial was the first time ever that a treatment method has demonstrated reversal of established disability in MS patients.
Stem Cell Treatment for MS Reverses Disability in Patients
For more than 20 years, Dr. Saud Sadiq has aimed to merge clinical excellence with innovative research targeted at finding the cure for multiple sclerosis. Today, the Tisch MS Research Center of New York, a non-profit research center, has a close relationship with its affiliated clinical practice, the International Multiple Sclerosis Management Practice.
This partnership enables the testing of new MS treatments and accelerates the pace at which research discoveries are translated into clinical practice, as demonstrated by the center’s innovative work with use of neural progenitors derived from bone marrow mesenchymal stem cells. [Read more…]